Navigation Links
LLS's Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
Date:9/20/2012

WHITE PLAINS, N.Y., Sept. 20, 2012 /PRNewswire/ -- Thanks to support funding from The Leukemia & Lymphoma Society (LLS), Onconova Therapeutics, Inc. has been advancing rigosertib, the lead compound under development for treating patients with high-risk myelodysplastic syndrome (MDS). 

In an announcement made this week, European commercial rights for rigosertib have been licensed to Baxter International providing significant resources to advance the program toward U.S. and European regulatory review and ultimately to MDS patients.  Rigosertib is designed to inhibit critical pathways to the growth and survival of cancer cells. 

"Advancing new therapies in areas of unmet medical need such as MDS is the bow of the ship for LLS," said LLS President and CEO John Walter. "The Baxter/Onconova agreement highlights a successful outcome for the LLS Therapy Acceleration Program (TAP)."

LLS and Onconova first announced their collaboration in June 2010. LLS has committed to providing up to $12.5 million in funding to support an ongoing multicenter, randomized, clinical trial of rigosertib versus best supportive care in adult patients with MDS who have relapsed or become resistant to azacitidine or decitabine. Onconova has announced that, to date, trial enrollment has successfully surpassed the half-way point and there are now 80 trial sites activated around the globe.  Onconova is continuing to accrue patients for the clinical trial.

This partnership marks the first phase 3, approval-track clinical trial that LLS is supporting through TAP, a bold initiative designed to bring promising therapies to patients suffering from blood cancers more quickly.  LLS is taking an active role in accelerating development of novel therapies for patients and&#
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
2. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
3. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
5. New gene therapy strategy boosts levels of deficient protein in Friedreichs ataxia
6. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
7. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
8. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
9. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
10. Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
11. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... DUBLIN , July 29, 2015 ... ) has announced the addition of the ... to their offering. The Global Biosimilars ... study of the rapidly growing biosimilars market. With ... industry striving to minimize costs, biosimilars are being ...
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index ... , in particular, drug/device combinations. The current system received a score of 0 (range ... Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ...
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
... Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") ... to date this year and guidance on its projected financial ... , ... 4.60 million (US $0.68 million), representing a 127 percent increase ...
... , Connecticut MORRISVILLE, N.C., May 20 Asymchem ... and Drug Products to the pharmaceutical industry, with sites in ... award by Pfizer Inc. as the 2008 Top Intermediates CMO ... center on May 1, 2009. The award was the first ...
Cached Biology Technology:Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... Whether it's rice farming or rice research, very few of ... career in an industry that has been a foundation of ... want their children to be rice farmers, and even fewer ... vital importance to the region. , However, an innovative ...
... sound like Saturday cartoons: a strong-boned rat that can't ... the real hero is citrus juice. , Orange and ... long considered an unavoidable aging disease in which bones ... by Texas A&M University's Vegetable and Fruit Improvement Center ...
... more than 25 million people in sub-Saharan Africa, according ... a vaccine against the virus have achieved limited success. ... infection found widely in that region of Africa ?chancroid ... of HIV as much as 10-fold? , That may ...
Cached Biology News:A rice future for Asia 2Orange, grapefruit juice for breakfast builds bones in rats 2Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3